Pharmaceuticals, Biotechnology and Life Sciences
An investigator-initiated trial at the National Institutes of Health (NIH) in an exploratory Phase I/II clinical trial in primary progressive…
Santhera Pharmaceuticals has reported an increase of 21% year-on-year in net revenues to CHF 22.9 million (2016: CHF 19.0 million)…
Santhera Pharmaceuticals will still remain without extension application for Raxone in Duchenne muscular dystrophy (DMD) in Europe, as expected. The…
Santhera Pharmaceuticals said on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…
Santhera Pharmaceuticals has enrolled first DMD patients with respiratory function decline not taking glucocorticoids into UK’s Early Access to Medicines…